

# Resource Summary Report

Generated by [dkNET](#) on Aug 3, 2026

## CUTC60

RRID:CVCL\_VM61

Type: Cell Line

### Proper Citation

RRID:CVCL\_VM61

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_VM61](https://web.expasy.org/cellosaurus/CVCL_VM61)

**Proper Citation:** RRID:CVCL\_VM61

**Description:** Cell line CUTC60 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Female

**Disease:** Thyroid gland anaplastic carcinoma

**Defining Citation:** [PMID:30733375](#), [PMID:30737244](#)

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** CUTC60

**Cross References:** cancercellines:CVCL\_VM61, Wikidata:Q93460551

**ID:** CVCL\_VM61

**Record Creation Time:** 20220427T215527+0000

**Record Last Update:** 20260801T235527+0000

### Ratings and Alerts

No rating or validation information has been found for CUTC60.

No alerts have been found for CUTC60.

### Data and Source Information

Source: [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 4 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Kellett MD, et al. (2025) Focal adhesion kinase promotes ribosome biogenesis to drive advanced thyroid cancer cell growth and survival. *Frontiers in oncology*, 15, 1252544.

Hicks HM, et al. (2024) The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies. *Cancer biology & therapy*, 25(1), 2332000.

Hicks HM, et al. (2023) Fibronectin Contributes to a BRAF Inhibitor-driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2. *Molecular cancer research : MCR*, 21(9), 867.

Bolf EL, et al. (2023) Dasatinib and Trametinib Promote Anti-Tumor Metabolic Activity. *Cells*, 12(10).